Individualized doxorubicin sensitivity testing of undifferentiated soft tissue sarcoma (USTS) in a patient-derived orthotopic xenograft (PDOX) model demonstrates large differences between patients

Doxorubicin (DOX) is often first-line treatment of undifferentiated/unclassified soft tissue sarcoma (USTS). However, the DOX response rate for USTS patients is low. Individualized precision-medicine technology that could identify DOX responders as well as non-responders would be of high value to ca...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Cell Cycle
Hlavní autoři: Kawaguchi, Kei, Igarashi, Kentaro, Kiyuna, Tasuku, Miyake, Kentaro, Miyake, Masuyo, Murakami, Takashi, Chmielowski, Bartosz, Nelson, Scott D., Russell, Tara A., Dry, Sarah M., Li, Yunfeng, Singh, Arun S., Unno, Michiaki, Eilber, Fritz C., Hoffman, Robert M.
Médium: Artigo
Jazyk:Inglês
Vydáno: Taylor & Francis 2018
Témata:
Reports
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5969558/
https://ncbi.nlm.nih.gov/pubmed/29384032
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/15384101.2017.1421876
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky